Get the Stockscreener App
14.91
1.08%
0.16
After Hours:
14.66
-0.25
-1.68%
Avidity Biosciences Inc stock is traded at $14.91, with a volume of 3.20M.
It is up +1.08% in the last 24 hours and down -79.50% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. The company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$14.75
Open:
$13.81
24h Volume:
3.20M
Relative Volume:
1.31
Market Cap:
$2.30B
Revenue:
$10.73M
Net Income/Loss:
$-455.74M
P/E Ratio:
-4.1919
EPS:
-3.5569
Net Cash Flow:
$-502.70M
1W Performance:
-79.55%
1M Performance:
-79.50%
6M Performance:
-68.43%
1Y Performance:
-51.34%
1-Day Range:
$13.81
$15.51
1-Week Range:
$13.06
$72.98
52-Week Range:
$13.06
$73.06
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
14.91 | 11.25B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Roth Capital | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Bernstein | Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Jun-11-25 | Initiated | Raymond James | Strong Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Novartis completes $12 billion acquisition of Avidity Biosciences - Indian Pharma Post
Atrium Therapeutics Stock Pre-Market (-4.5%): Launch as Public Company Post-Spin-Off - Trefis
Avidity Biosciences (NASDAQ:RNA) Reaches New 12-Month LowHere's What Happened - MarketBeat
Novartis completes $12 billion Avidity Biosciences acquisition By Investing.com - Investing.com Canada
Atrium Arises From Novartis’s Avidity Buyout - Citeline News & Insights
Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger - Yahoo Finance
Merger cashout for Avidity Biosciences (RNA) director Simona Skerjanec - Stock Titan
Avidity Biosciences (RNA) CLO disposes stock, options in Novartis merger - Stock Titan
[Form 4] Avidity Biosciences, Inc. Insider Trading Activity - Stock Titan
Merger cash-out: Avidity Biosciences (RNA) officer’s options and shares disposed - Stock Titan
Novartis buyout: Avidity Biosciences (NASDAQ: RNA) director’s equity cashed out - Stock Titan
Avidity Biosciences (RNA) CTO equity disposed in $72 Novartis merger - Stock Titan
Avidity Biosciences shareholders approve merger with Novartis By Investing.com - Investing.com Australia
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA - BioPharma Dive
Operating expenses (excl. COGS) of Avidity Biosciences, Inc. – NASDAQ:RNAM - TradingView
Atrium Tx launches with Avidity's RNA ticker and cardio assets - bioworld.com
Avidity-Novartis deal spins out Atrium Therapeutics - The Pharma Letter
Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates - Fierce Biotech
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week HighHere's What Happened - MarketBeat
Novartis completes acquisition of Avidity Biosciences - TipRanks
Avidity Biosciences Completes Merger and Plans Nasdaq Delisting - TipRanks
[POSASR] Avidity Biosciences, Inc. SEC Filing - Stock Titan
As Novartis deal closes, Avidity's rare heart disease spinout launches with $270M - Endpoints News
Novartis (NVS) Completes Acquisition of Avidity Biosciences - GuruFocus
Novartis Completes Acquisition of Avidity Biosciences - marketscreener.com
Novartis completes acquisition of Avidity Biosciences; shares to be delisted from Nasdaq - Investing.com
Novartis Closes $12 Billion Acquisition of Avidity Biosciences - marketscreener.com
Avidity Biosciences Ends ATM Sales Agreement With TD Securities Following Novartis Merger Close - TradingView
Avidity Biosciences Inc (RNAM-Q) Stock Price and News - The Globe and Mail
New RNA drugmaker launches with $270M for rare cardiomyopathies - Stock Titan
Novartis completes $12 billion Avidity Biosciences acquisition - Investing.com
Why Is Avidity Biosciences Stock (RNA) Down Today? - TipRanks
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy - Novartis
Avidity Biosciences (RNAM) Peg Ratio (TTM) - Zacks Investment Research
S&P 500 Futures Decline In Premarket Trading; Avidity Biosciences, Duolingo Lag - 富途牛牛
S&P 500 Futures Decline in Premarket Trading; Avidity Biosciences, Duolingo Lag - Barron's
Avidity Biosciences, Inc. $RNA Shares Bought by JPMorgan Chase & Co. - MarketBeat
Why Avidity Biosciences Shares Are Sliding Now - TipRanks
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - BioSpace
Avidity Shareholders Approve Novartis Merger and Spin-Off - TipRanks
Avidity Biosciences shareholders approve merger with Novartis - Investing.com
Avidity Biosciences (RNA) investors approve Novartis merger and Atrium spin-off - Stock Titan
One-year Duchenne study ties treatment to near-normal creatine kinase levels - Stock Titan
Cash from financing activities of Avidity Biosciences, Inc. – NASDAQ:RNAM - TradingView
Promising Medical Stocks To Follow TodayFebruary 26th - MarketBeat
Promising Pharmaceutical Stocks To Follow NowFebruary 26th - MarketBeat
Avidity Biosciences, Inc. Cash Flow – NASDAQ:RNAM - TradingView
Avidity Biosciences, Inc. Balance Sheet – NASDAQ:RNAM - TradingView
Avidity Biosciences, Inc. Financial Statements – NASDAQ:RNAM - TradingView
Net income of Avidity Biosciences, Inc. – NASDAQ:RNAM - TradingView
Avidity Biosciences, Inc. Revenue Breakdown – NASDAQ:RNAM - TradingView
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.90%
2.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):